Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NOBLE: Neoadjuvant Olaparib and Durvalumab in BRCA-associated Triple Negative Breast Cancer
2022-003594-33Phase 2Terminated
- Sponsor
- European Organisation for Research and Treatment of Cancer
- Start
- Jan 2023
- Modality
- PD-1/PD-L1 Inhibitors → Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of olaparib and durvalumab in triple-negative breast cancer (TNBC) (2 arms), sponsored by European Organisation for Research and Treatment of Cancer. Primary endpoint: Pathological complete response rate. Started Jan 2023; status: terminated.
02
Drugs
olaparibdurvalumab
03
Conditions
triple-negative breast cancer (TNBC)
Beyond the preview
Go deeper on 2022-003594-33.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-003594-33.